BusinessSummit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society CongressBy Nasdaq OMXJun 22, 2017, 11:00 AM UTC
BusinessSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentBy Nasdaq OMXJan 18, 2017, 12:01 PM UTC
BusinessSummit Appoints Dr David Roblin as Chief Operating Officer and President of Research & DevelopmentBy Nasdaq OMXJan 18, 2017, 12:01 PM UTC
BusinessSummit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMDBy Nasdaq OMXNov 16, 2016, 12:00 PM UTC
BusinessSummit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle SocietyBy Nasdaq OMXOct 6, 2016, 11:00 AM UTC
BusinessSarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXOct 4, 2016, 11:00 AM UTC
BusinessSummit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 27, 2016, 11:00 AM UTC
BusinessSummit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 26, 2016, 11:00 AM UTC
